Cameron Brooks Sells 1,242 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the completion of the sale, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise Trading Down 3.9%

AXON opened at $452.51 on Wednesday. The company’s 50 day moving average is $408.90 and its 200-day moving average is $490.57. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The company has a market cap of $36.47 billion, a P/E ratio of 181.73, a PEG ratio of 8.56 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same period last year, the company posted $1.47 EPS. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. Equities research analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Barclays cut their target price on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada cut their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC cut their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds have recently added to or reduced their stakes in the business. NEOS Investment Management LLC lifted its position in shares of Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after purchasing an additional 11,482 shares during the period. Legal & General Group Plc lifted its position in shares of Axon Enterprise by 1.3% in the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after purchasing an additional 5,419 shares during the period. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of Axon Enterprise in the 4th quarter worth approximately $13,116,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Axon Enterprise by 93.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after purchasing an additional 11,262 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon continues to receive favorable analyst coverage, with a “Moderate Buy” consensus and an average price target of $712.75, suggesting Wall Street still sees meaningful upside from current levels.
• Positive Sentiment: The stock has also been supported by strong recent fundamentals, including the company’s latest earnings beat and revenue growth, which helped drive a strong run earlier in the month. Article Title
• Neutral Sentiment: AXON Networks announced the acquisition of Greenwave Systems, a deal that expands its OSS/BSS and wireless orchestration capabilities. This is a strategic growth update, but it appears unrelated to Axon Enterprise’s core public-safety business. Article Title
• Neutral Sentiment: Short-interest data showed no meaningful change in the near term, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Several insiders, including the CEO, president, and CRO, sold shares under pre-arranged trading plans. While these sales may be routine, they can still weigh on investor sentiment when the stock is already trading lower. Article Title
• Negative Sentiment: The stock’s recent pullback also reflects broader profit-taking after a strong monthly run, especially as Axon remains richly valued versus earnings.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.